Coeptis Therapeutics Holdings Inc (COEP)
$0.22
+0.01
(+5.26%)▲
Live
Performance
- $0.20$0.23$0.22
9.05%
Downside
Day's Volatility :12.96%
Upside
4.31%
- $0.15$1.38$0.22
31.32%
Downside
52 Weeks Volatility :89.05%
Upside
84.06%
Returns
| Period | Coeptis Therapeutics Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -24.54% | 0.0% |
6 Months | -41.01% | 0.0% |
1 Year | -84.6% | 0.0% |
3 Years | -95.62% | -23.0% |
Highlights
Market Capitalization | 7.9M |
Book Value | -$0.01 |
Earnings Per Share (EPS) | -0.47 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -187.35% |
Return On Equity TTM | -1481.29% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 1563.7% |
Gross Profit TTM | 75.0K |
EBITDA | -16.0M |
Diluted Eps TTM | -0.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.26 |
EPS Estimate Next Year | -0.17 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1263.64%
Technicals Summary
Sell
Neutral
Buy
Coeptis Therapeutics Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Coeptis Therapeutics Holdings Inc | 17.64% | -41.01% | -84.6% | -95.62% | -95.62% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Coeptis Therapeutics Holdings Inc | NA | NA | NA | -0.26 | -14.81 | -1.87 | NA | -0.01 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Coeptis Therapeutics Holdings Inc | Buy | $7.9M | -95.62% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Coeptis Therapeutics Holdings Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 165.6%
Institutional Holdings
Creative Planning Inc
1.62%Meteora Capital, LLC
1.12%Geode Capital Management, LLC
0.50%Vanguard Group Inc
0.25%CAMBRIDGE Invest RESEARCH ADVISORS, INC.
0.14%Arista Wealth Management LLC
0.12%
Company Information
Organization | Coeptis Therapeutics Holdings Inc |
Employees | 5 |
CEO | Mr. David Mehalick |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.22
+5.26%
Invesco Bulletshares 2025 Hi
$0.22
+5.26%
Schwab International Dividend Equity Etf
$0.22
+5.26%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.22
+5.26%
Lightpath Technologies Inc
$0.22
+5.26%
Vaneck Vectors Global Alternative Energy Etf
$0.22
+5.26%
First Trust Flexible Municipal High Income Etf
$0.22
+5.26%
Drx Dly Reg Bank Bull 3x
$0.22
+5.26%
Graniteshares 2x Long Pltr Daily Etf
$0.22
+5.26%